{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T13:56:55Z","timestamp":1783951015116,"version":"3.55.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,9]],"date-time":"2021-11-09T00:00:00Z","timestamp":1636416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006939","name":"Emory University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006939","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019428","name":"Nabriva Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019428","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jgar.2021.10.021","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T10:01:19Z","timestamp":1636884079000},"page":"434-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin"],"prefix":"10.1016","volume":"29","author":[{"given":"Susanne","family":"Paukner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita F.","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8212-9064","authenticated-orcid":false,"given":"Pritty","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Sandrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Thomas M.","family":"File","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge E.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken B.","family":"Waites","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Gelone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Schranz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.10.021_bib0001","article-title":"Deaths: final data for 2016. US Department of Health and Human Services","author":"Xu","year":"2018","journal-title":"Centers for Disease Control and Prevention, National Center for Health Statistics"},{"key":"10.1016\/j.jgar.2021.10.021_bib0002","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/17476348.2019.1562339","article-title":"The burden of community-acquired bacterial pneumonia in the era of antibiotic resistance","volume":"13","author":"Peyrani","year":"2019","journal-title":"Expert Rev Respir Med"},{"key":"10.1016\/j.jgar.2021.10.021_bib0003","series-title":"Antibiotic resistance threats in the United States, 2019","year":"2019"},{"key":"10.1016\/j.jgar.2021.10.021_bib0004","series-title":"Surveillance of antimicrobial resistance in Europe 2018","year":"2019"},{"key":"10.1016\/j.jgar.2021.10.021_bib0005","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2021.10.021_bib0006","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.idc.2019.07.002","article-title":"Antibiotic-resistant community-acquired bacterial pneumonia","volume":"33","author":"Ho","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jgar.2021.10.021_bib0007","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/14740338.2019.1665022","article-title":"An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin-association neuropsychiatric toxicities, long-term disability, and aortic aneurysms\/dissections disseminated by the Food and Drug Administration and the European Medicines Agency","volume":"18","author":"Bennett","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jgar.2021.10.021_bib0008","series-title":"FDA drug safety communication: FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes","year":"2018"},{"key":"10.1016\/j.jgar.2021.10.021_bib0009","series-title":"XenletaTM (lefamulin). Full prescribing information","year":"2019"},{"key":"10.1016\/j.jgar.2021.10.021_bib0010","doi-asserted-by":"crossref","first-page":"39004","DOI":"10.1038\/srep39004","article-title":"A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism","volume":"6","author":"Eyal","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2021.10.021_bib0011","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a027110","article-title":"Pleuromutilins: potent drugs for resistant bugs\u2014mode of action and resistance","volume":"7","author":"Paukner","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jgar.2021.10.021_bib0012","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/jac\/dks001","article-title":"Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)","volume":"67","author":"Sader","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.10.021_bib0013","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1128\/AAC.00627-16","article-title":"In vitro activity of lefamulin tested against Streptococcus pneumoniae with defined serotypes, including multidrug-resistant isolates causing lower respiratory tract infections in the United States","volume":"60","author":"Mendes","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.021_bib0014","doi-asserted-by":"crossref","first-page":"e02008","DOI":"10.1128\/AAC.02008-16","article-title":"In vitro activities of lefamulin and other antimicrobial agents against macrolide-susceptible and macrolide-resistant Mycoplasma pneumoniae from the United States, Europe, and China","volume":"61","author":"Waites","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.10.021_bib0015","doi-asserted-by":"crossref","first-page":"e02161","DOI":"10.1128\/AAC.02161-18","article-title":"Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY antimicrobial surveillance program (2015\u20132016)","volume":"63","author":"Paukner","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.10.021_bib0016","doi-asserted-by":"crossref","first-page":"iii19","DOI":"10.1093\/jac\/dkz087","article-title":"Pharmacokinetics and tolerability of lefamulin following intravenous and oral dosing","volume":"74","author":"Wicha","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.10.021_bib0017","doi-asserted-by":"crossref","first-page":"iii27","DOI":"10.1093\/jac\/dkz088","article-title":"Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using phase 1 data and population pharmacokinetics methods","volume":"74","author":"Zhang","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.10.021_bib0018","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/cid\/ciz090","article-title":"Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial","volume":"69","author":"File","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.021_bib0019","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1001\/jama.2019.15468","article-title":"Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial","volume":"322","author":"Alexander","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2021.10.021_bib0020","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12890-021-01472-z","article-title":"Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities","volume":"21","author":"File","year":"2021","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jgar.2021.10.021_bib0021","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2016"},{"key":"10.1016\/j.jgar.2021.10.021_bib0022","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0, 2016. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_6.0_Breakpoint_table.xls (Accessed 16 January 2021)."},{"key":"10.1016\/j.jgar.2021.10.021_bib0023","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/JCM.00321-07","article-title":"Sensitive detection of Mycoplasma pneumoniae in human respiratory tract samples by optimized real-time PCR approach","volume":"45","author":"Dumke","year":"2007","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2021.10.021_bib0024","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/INF.0b013e31819e3f7a","article-title":"Emerging macrolide resistance in Mycoplasma pneumoniae in children: detection and characterization of resistant isolates","volume":"28","author":"Li","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2021.10.021_bib0025","series-title":"Clinical microbiology procedures handbook","article-title":"Detection of human mycoplasmas and ureaplasmas from clinical specimens by culture and PCR","author":"Waites","year":"2016"},{"key":"10.1016\/j.jgar.2021.10.021_bib0026","series-title":"Methods for antimicrobial susceptibility testing for human mycoplasmas. CLSI document M43-A","year":"2011"},{"key":"10.1016\/j.jgar.2021.10.021_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167725","article-title":"Increased nasopharyngeal density and concurrent carriage of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis are associated with pneumonia in febrile children","volume":"11","author":"Chochua","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.10.021_bib0028","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jmoldx.2012.06.001","article-title":"Molecular methods for the detection of Mycoplasma and Ureaplasma infections in humans: a paper from the 2011 William Beaumont Hospital symposium on molecular pathology","volume":"14","author":"Waites","year":"2012","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.jgar.2021.10.021_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.diagmicrobio.2010.11.014","article-title":"Detection of Mycoplasma pneumoniae, Chlamydia pneumoniae, and Legionella spp. in clinical specimens using a single-tube multiplex real-time PCR assay","volume":"70","author":"Thurman","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.021_bib0030","doi-asserted-by":"crossref","first-page":"788.e1","DOI":"10.1016\/j.cmi.2015.05.004","article-title":"Development of two real-time multiplex PCR assays for the detection and quantification of eight key bacterial pathogens in lower respiratory tract infections","volume":"21","author":"Gadsby","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2021.10.021_bib0031","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1128\/JCM.01553-14","article-title":"Genomic load from sputum samples and nasopharyngeal swabs for diagnosis of pneumococcal pneumonia in HIV-infected adults","volume":"52","author":"Albrich","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2021.10.021_bib0032","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1086\/648678","article-title":"Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods","volume":"50","author":"Johansson","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.021_bib0033","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.diagmicrobio.2006.01.007","article-title":"Quantitative detection of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in lower respiratory tract samples by real-time PCR","volume":"55","author":"Kais","year":"2006","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.021_bib0034","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3390\/pathogens4020199","article-title":"Direct detection of methicillin-resistant Staphylococcus aureus in sputum specimens from patients with hospital-associated pneumonia using a novel multilocus PCR assay","volume":"4","author":"Huang","year":"2015","journal-title":"Pathogens"},{"key":"10.1016\/j.jgar.2021.10.021_bib0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.jgar.2021.10.021_bib0036","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2017"},{"key":"10.1016\/j.jgar.2021.10.021_bib0037","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2018"},{"key":"10.1016\/j.jgar.2021.10.021_bib0038","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/civ1214","article-title":"Comprehensive molecular testing for respiratory pathogens in community-acquired pneumonia","volume":"62","author":"Gadsby","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.021_bib0039","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/cid\/cir274","article-title":"Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study","volume":"53","author":"Chalmers","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.021_bib0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jinf.2013.03.003","article-title":"Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: results of a one-year study","volume":"67","author":"Musher","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.jgar.2021.10.021_bib0041","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among US adults","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2021.10.021_bib0042","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3947\/ic.2013.45.4.351","article-title":"Diagnosis of pneumococcal pneumonia: current pitfalls and the way forward","volume":"45","author":"Song","year":"2013","journal-title":"Infect Chemother"},{"key":"10.1016\/j.jgar.2021.10.021_bib0043","series-title":"Guidance for industry. Community-acquired bacterial pneumonia: developing drugs for treatment. US Department of Health and Human Services","year":"2020"},{"key":"10.1016\/j.jgar.2021.10.021_bib0044","doi-asserted-by":"crossref","first-page":"e21042","DOI":"10.1371\/journal.pone.0021042","article-title":"PCR improves diagnostic yield from lung aspiration in Malawian children with radiologically confirmed pneumonia","volume":"6","author":"Carrol","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2021.10.021_bib0045","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1128\/JCM.37.3.709-714.1999","article-title":"Usefulness of PCR and antigen latex agglutination test with samples obtained by transthoracic needle aspiration for diagnosis of pneumococcal pneumonia","volume":"37","author":"Garc\u00eda","year":"1999","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2021.10.021_bib0046","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccm.2016.11.004","article-title":"Diagnosing viral and atypical pathogens in the setting of community-acquired pneumonia","volume":"38","author":"Waterer","year":"2017","journal-title":"Clin Chest Med"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.10.021_bib0047","first-page":"iii19","article-title":"FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"File","year":"2011","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.10.021_bib0048","doi-asserted-by":"crossref","first-page":"iii33","DOI":"10.1093\/jac\/dkr097","article-title":"FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia","volume":"66","author":"Low","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.10.021_bib0049","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/cid\/ciw490","article-title":"SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia","volume":"63","author":"File","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.021_bib0050","first-page":"ofz514","article-title":"A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2021.10.021_bib0051","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/cid\/ciaa246","article-title":"Geographic shifts in antibacterial drug clinical trial enrollment: implications for generalizability","volume":"72","author":"Bart","year":"2021","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521002459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:00:35Z","timestamp":1761991235000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521002459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":51,"alternative-id":["S2213716521002459"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.021","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pooled microbiological findings and efficacy outcomes by pathogen in adults with community-acquired bacterial pneumonia from the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 phase 3 trials of lefamulin versus moxifloxacin","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}